Browse studies

Find your next paid study

3,226 recruiting studies matching your filters

A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refra…

B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Vironexis Biotherapeutics Inc.NCT06533579

Phase 2

A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 …

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

University of California, San FranciscoNCT07110246

Understanding the Outcomes and Rationale for Treatment Decisions in Patients With Intermediate and High-risk Nonmuscle Invasive Bladder Cancer and Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer: A Multi-center Prospective Observational Trial.

This study aims to better understand how treatment choices impact outcomes for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NM…

NMIBCMIBCMuscle Invasive Bladder Cancer (MIBC)+1 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Bladder Cancer Advocacy NetworkNCT07893509

Phase 2

A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-…

Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell Carcinoma+19 more

Estimated

Phase 2

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to…

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell Carcinoma+15 more

Estimated

Phase 3

A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sp…

Advanced CancerMetastatic Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Daiichi SankyoNCT06174987

Phase 2

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) a…

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

Estimated

~$75 – $2,800

Actual pay is set by the research site.

CatalYm GmbHNCT07246863

Phase 2

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolli…

Advanced Solid TumorMelanomaHead and Neck Cancer+11 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Daiichi SankyoNCT06172478

Phase 1

A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients w…

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06015880

Observational

A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.

This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement,…

Improves Daytime Energy LevelsReduces Afternoon Energy Crashes and Midday FatigueImproves Overall Sleep Quality and Restorative Sleep+7 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Phase 1

Phase 1 /2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer.

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomogr…

Prostate Cancer (Adenocarcinoma)Adenocarcinoma of the ProstateMetastatic Castration-resistant Prostate Cancer (mCRPC)+3 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

RayzeBio, Inc.NCT07862582

Phase 1

A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given …

Locally Advanced or Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07730021